Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.6052W HIGH $4.94
Volume
448.97 K
Value Traded
1.31 M
Short % Float
11.15%
-5.67%Week
-6.63%1 Month
-3.68%3 Month
-32.72%6 Month
-84.39%5 Year
-93.09%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
105.14 M
EPS (TTM)
-0.74
P/E Ratio
-
Ent. Value
-5.37 M
Total Shares
57.41 M
Float Shares
46.15 M
Insiders
19.67%
Institutions
54.53%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
BDTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Black Diamond Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Black Diamond Therapeutics, Inc.
333Total events
13Upcoming
41Tier-1 (high impact)
2019 to 2028Coverage
Upcoming catalysts 2
Event history 50
●Enrollment UpdateSilevertinibTrial
Phase 2 GBM trial enrolling patients in safety lead-in
newly diagnosed EGFRvIII-positive glioblastoma (GBM)source ↗
◆Oral PresentationPresentation
CEO to participate in fireside chat at Jefferies Global Healthcare Conference
◆Poster PresentationSilevertinibPresentation
Trial-in-progress poster presentation of randomized Phase 2 study of silevertinib in newly diagnosed GBM at ASCO 2026
EGFRvIII-positive IDHwt MGMT unmethylated glioblastomasource ↗
◆Poster PresentationSilevertinibPresentation
Poster presentation of Phase 2 safety and efficacy data for silevertinib in previously treated NSCLC patients at ASCO 2026
non-small cell lung cancer with non-classical and C797S EGFR mutationssource ↗
▲Oral PresentationSilevertinibPresentation
Positive Phase 2 results for silevertinib presented at ASCO 2026
frontline non-classical EGFR-mutant NSCLCsource ↗
◆Oral PresentationSilevertinibPresentation
Webcast to present updated results from Phase 2 trial of silevertinib in 1L EGFRm NSCLC
EGFR mutated non-small cell lung cancersource ↗
▲Topline ReadoutSilevertinibClinical Data
Positive Phase 2 results for silevertinib in 1L NSCLC with EGFR-NCMs
frontline non-small cell lung cancer with EGFR non-classical mutationssource ↗
▲First Patient DosedSilevertinibTrial
First patient dosed in Phase 2 trial of silevertinib in combination with TMZ in newly diagnosed EGFRvIII+ GBM
newly diagnosed EGFRvIII+ GBMsource ↗
▲Trial InitiationSilevertinibTrial
Initiated randomized Phase 2 trial in newly diagnosed EGFRvIII-positive GBM
EGFRvIII-positive GBMsource ↗
◆Oral PresentationSilevertinibPresentation
Updated results from Phase 2 NSCLC trial including DOR and PFS data to be presented at a medical meeting
non-small cell lung cancer (NSCLC) with non-classical EGFR mutationssource ↗
◆Trial InitiationSilevertinibTrial
Initiation of randomized Phase 2 trial of silevertinib in newly diagnosed EGFRvIII-positive GBM
newly diagnosed EGFRvIII-positive glioblastomasource ↗
◆Topline ReadoutSilevertinibClinical Data
Updated clinical data from Phase 2 trial of silevertinib in non-classical EGFRm NSCLC including preliminary DOR and PFS in frontline setting
non-classical EGFRm NSCLCsource ↗
◆Oral PresentationSilevertinibPresentation
Webcast presenting Phase 2 clinical trial results and program update for silevertinib
non-small cell lung cancer (NSCLC)source ↗
▲Topline ReadoutSilevertinibClinical Data
Preliminary Phase 2 data for silevertinib in 1L NSCLC announced
frontline non-small cell lung cancer (NSCLC) with non-classical EGFR mutationssource ↗
▲Topline ReadoutSilevertinibClinical Data
Initial Phase 2 data disclosed in December 2025 for frontline NSCLC
non-small cell lung cancer with non-classical EGFR mutationssource ↗
◆Oral PresentationPresentation
Participation in upcoming investor conferences with webcast presentations
◆Timing GuidanceSilevertinibPresentation
Clinical update from silevertinib Phase 2 trial in newly diagnosed EGFRm NSCLC expected later Q4 2025
EGFRm NSCLCsource ↗
◆Topline ReadoutSilevertinibClinical Data
ORR and preliminary DOR data from Phase 2 trial of silevertinib in 1L NSCLC
non-small cell lung cancer (NSCLC) with non-classical EGFR mutationssource ↗
◆Topline ReadoutSilevertinibClinical Data
Initial Phase 2 clinical data for BDTX-1535 in newly diagnosed patients with non-classical EGFRm NSCLC
non-classical EGFRm NSCLCsource ↗
◆FDA Feedback ReceivedSilevertinibFDA Meeting
FDA feedback on potential pivotal registrational path for BDTX-1535
non-classical EGFRm NSCLCsource ↗
▲Enrollment CompleteSilevertinibTrial
Enrollment completed for Phase 2 trial of silevertinib in 1L NSCLC with non-classical EGFR mutations
non-small cell lung cancer (NSCLC) with non-classical EGFR mutationssource ↗
◆Oral PresentationPresentation
Participation in Jefferies Global Healthcare Conference fireside chat
◆Oral PresentationPresentation
24th Annual Needham Virtual Healthcare Conference presentation
◆Topline ReadoutSilevertinibClinical Data
Initial Phase 2 clinical data in newly diagnosed patients with non-classical EGFRm NSCLC
non-classical EGFRm NSCLCsource ↗
▲Poster PresentationSilevertinibPresentation
Poster presentation at AACR 2025: Phase 0/1 'trigger' trial of BDTX-1535 in recurrent GBM
recurrent GBM with EGFR alterations or fusionssource ↗
▲Partnership / LicenseBDTX-4933DiscontinuedCorporate
Global licensing agreement with Servier for BDTX-4933
RAF/RAS-mutant solid tumorssource ↗
▲Trial InitiationSilevertinibTrial
Expansion of investigator sponsored Phase 0/1 trial into newly diagnosed GBM patients with EGFR alterations
newly diagnosed GBM with EGFR alterationssource ↗
▲Partnership / LicenseBDTX-4933DiscontinuedCorporate
Global licensing agreement with Servier for BDTX-4933
RAF/RAS-mutant solid tumorssource ↗
▲Trial InitiationSilevertinibTrial
Expansion of investigator sponsored window of opportunity trial into Phase 0/2 trial in newly diagnosed GBM patients
newly diagnosed glioblastoma with EGFR aberrationssource ↗
◆Topline ReadoutSilevertinibClinical Data
Initial Phase 2 data in first-line NCM setting expected Q1 2025
first-line non-small cell lung cancer (NSCLC) with non-classical EGFR mutationssource ↗
Past FDA Catalysts and PDUFA Decisions
How BDTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | silevertinib | Phase 2 data presentation | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D35 / 100
Pipeline Score
$132M
Pipeline Value
Fair Value
Valuation Signal
1
Drugs Scored
1.3x
rNPV / MCap
Top 54%
Micro Cap(rank 357 of 660)
Percentile Rank
Black Diamond Therapeutics, Inc. faces pipeline headwinds (35/100), with $526M risk-adjusted pipeline value, led by Silevertinib in Non-Small Cell Lung Cancer (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Silevertinib Small moleculeNCT07326566 | Glioblastoma (GBM) | Phase 2 | RECRUITING | 162 | Mar 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every BDTX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| silevertinib | non-classical EGFR-mutant NSCLC | Phase 2 | 2026-08-05 | CNS objective response rate: 86%; Objective Response Rate (ORR): 60%; Disease Control Rate (DCR): 91%; Median duration of response: not reached; Preliminary median progression free survival: 15.2 months; Patients remaining on therapy: 23 of 43 (53%)Read More | Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Behbahani AliDirector | Grant/Award | 40,000 40,000 held | $0.00 | 06/26/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BDTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| NEA Management Company, LLC | 0.5 % | 8.23 M | 4.45 M |
BDTX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-12-18 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BDTX ranks across every disease it competes in
Competitive Position is a premium feature
See how BDTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBDTX News
BDTXBlack Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
Black Diamond Therapeutics will participate in the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. Chief Scientific Officer Elizabeth Buck will lead a fireside chat, and the company will hold one-on-one meetings with investors. The event highlights the company's focus on developing silevertinib, a promising EGFR inhibitor for cancer treatment.
Read more →BDTX▲ +7.3%on this news
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Black Diamond Therapeutics reported positive Phase 2 results for silevertinib in patients with non-classical EGFR-mutant NSCLC, highlighting an 86% CNS objective response rate and no new brain metastases. The company anticipates updates on the trial and FDA feedback in Q4 2026. Financially, they ended Q2 2026 with $110.5 million, sufficient to support operations until 2028.
Read more →BDTX▼ -35.8%on this news
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
Black Diamond Therapeutics, a clinical-stage oncology company, will participate in the Jefferies Global Healthcare Conference on June 3, 2026. CEO Mark Velleca will engage in a fireside chat, and the company will also host one-on-one meetings with investors. The announcement highlights the company's focus on developing MasterKey therapies to target mutations in cancer patients. A webcast of the presentation will be available on their website, with a replay archived for 90 days.
Read more →BDTXBlack Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
Black Diamond Therapeutics announced positive Phase 2 results for silevertinib in frontline non-small cell lung cancer (NSCLC) patients with EGFR non-classical mutations. The trial showed a preliminary median progression-free survival of 15.2 months and a 60% overall response rate. Notably, there were no new brain metastases among patients, highlighting the drug's robust CNS activity. The company plans to discuss pivotal development plans with the FDA later this year.
Read more →BDTX▲ +16.3%on this news· ran to +40% by day 1shared move
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
Black Diamond Therapeutics will host a webcast on May 21, 2026, to present updated results from its Phase 2 trial of silevertinib for patients with EGFR mutated non-small cell lung cancer. The event aims to inform investors about the ongoing developments in the trial. A replay will be available post-event.
Read more →BDTXBlack Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Black Diamond Therapeutics reported its Q1 2026 financial results, highlighting the dosing of the first patient in a Phase 2 trial for EGFRvIII+ GBM. The company has a strong cash position of $118.3 million, sufficient to fund operations into the second half of 2028. Upcoming presentations at the 2026 ASCO Annual Meeting will showcase data on silevertinib for NSCLC and GBM.
Read more →BDTXBlack Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
Black Diamond Therapeutics announced multiple presentations at the 2026 ASCO Annual Meeting, including an oral presentation on the Phase 2 study of silevertinib in treatment-naïve patients with non-small cell lung cancer (NSCLC) featuring non-classical EGFR mutations. The company also plans to present data on silevertinib in recurrent NSCLC and glioblastoma patients. Initial data indicated a 60% Objective Response Rate in frontline NSCLC patients.
Read more →BDTXBlack Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Black Diamond Therapeutics reported its financial results for Q4 and full year 2025, highlighting a strong cash position of $128.7 million. The company is on track to present updated clinical data from its Phase 2 trial of silevertinib in non-classical EGFRm NSCLC in Q2 2026 and plans to initiate a randomized Phase 2 trial in newly diagnosed EGFR altered GBM. The company has shown a significant objective response rate in its ongoing trials.
Read more →BDTX▼ -5.3%on this news
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - March 2, 2026
Black Diamond Therapeutics announced its participation in upcoming investor conferences, including the Raymond James BioPharma Conference on April 14, 2026. The company's leadership, including CEO Mark Velleca and CSO Elizabeth Buck, will present at these events. Webcasts will be available for live viewing and archived for 90 days.
Read more →BDTX▼ -22%on this news
Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM
Black Diamond Therapeutics announced preliminary Phase 2 data for silevertinib in frontline NSCLC patients with non-classical EGFR mutations. The data indicates significant activity against 35 distinct mutations and shows promise for CNS involvement. The company also plans to initiate a randomized Phase 2 trial for silevertinib in newly diagnosed glioblastoma patients in 2026.
Read more →BDTX▼ -22%on this newsshared move
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update
Black Diamond Therapeutics will host a webcast on December 3, 2025, to present results from its Phase 2 clinical trial of silevertinib, a treatment targeting EGFR-mutant non-small cell lung cancer. The event will also provide a program update. A replay will be available after the live presentation.
Read more →BDTXBlack Diamond Therapeutics to Participate in Upcoming Investor Conferences
Black Diamond Therapeutics, a clinical-stage oncology company, announced its participation in upcoming investor conferences. CEO Mark Velleca will present details about the company's innovative MasterKey therapies aimed at treating genetically defined tumors. The presentations will be available via webcast, with replays accessible for 90 days.
Read more →BDTXBlack Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Black Diamond Therapeutics reported its third quarter 2025 financial results and provided an update on its silevertinib Phase 2 trial for EGFR-mutant NSCLC. The company anticipates sharing clinical data, including overall response rate and preliminary treatment duration, later this quarter. PFS data is expected in the first half of 2026, highlighting the ongoing development of its MasterKey therapies.
Read more →BDTX▼ -15.2%on this news
Document Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Enrollment completed for the Phase 2 trial of silevertinib (BDTX-1535) in 1L patients with non-classical EGF
Black Diamond Therapeutics reported its financial results for the second quarter of 2025, highlighting the completion of patient enrollment in the Phase 2 trial of silevertinib for first-line treatment of NSCLC. The company has sufficient cash reserves, reported at approximately $142.8 million, to support its operations until late 2027. Upcoming milestones include the expected release of objective response rate (ORR) and preliminary duration of response (DOR) data in Q4 2025, alongside plans to seek FDA feedback on its development path in 1H 2026.
Read more →BDTX▼ -15.2%on this news
Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Black Diamond Therapeutics reported its financial results for Q2 2025, highlighting the completion of patient enrollment for the Phase 2 trial of silevertinib in non-classical EGFR-mutant NSCLC. The company anticipates revealing objective response rate and preliminary duration of response data in Q4 2025. They are also exploring partnership opportunities to facilitate the pivotal development of silevertinib and plan to meet with the FDA regarding the drug's development pathway in 1H 2026. Black Diamond ended the quarter with $142.8 million in cash, expected to support operations until late 2027.
Read more →BDTX▲ +6.7%on this news· ran to +18% by day 1
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update Clinical data on track for Q4 2025 from Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC
Black Diamond Therapeutics reported its first quarter financial results for 2025, highlighting a strong cash position of $152.4 million, sufficient to support operations into Q4 2027. The company is progressing in its Phase 2 trial for BDTX-1535, with initial clinical data expected in Q4 2025. Additionally, a partnership with Servier for BDTX-4933 could provide up to $710 million in milestone payments. Despite these positives, uncertainties remain regarding the success of upcoming clinical trials and the risks associated with forward-looking statements.
Read more →About Black Diamond Therapeutics, Inc.
Headquarters245 FIRST STREET, 18TH FLOOR, CAMBRIDGE, MA, 02142
Founded2014
BIOPHARMAWATCH ELITE PLUS
Trade the next BDTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime